Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.00p +3.08% 67.00p 65.00p 69.00p 67.50p 65.00p 65.00p 129,164 11:52:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.3 -1.5 1.7 40.1 52.62

Optibiotix H. (OPTI) Latest News

More Optibiotix H. News
Optibiotix H. Takeover Rumours

Optibiotix H. (OPTI) Share Charts

1 Year Optibiotix H. Chart

1 Year Optibiotix H. Chart

1 Month Optibiotix H. Chart

1 Month Optibiotix H. Chart

Intraday Optibiotix H. Chart

Intraday Optibiotix H. Chart

Optibiotix H. (OPTI) Discussions and Chat

Optibiotix H. (OPTI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-07-21 16:07:3267.0015,50010,385.00O
2017-07-21 15:07:2668.901,127776.50O
2017-07-21 14:40:0368.901,400964.60O
2017-07-21 13:32:0168.665,0003,433.00O
2017-07-21 13:28:5768.6610068.66O
View all Optibiotix H. trades in real-time

Optibiotix H. (OPTI) Top Chat Posts

DateSubject
22/7/2017
09:20
Optibiotix H. Daily Update: Optibiotix H. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix H. was 65p.
Optibiotix H. has a 4 week average price of 61.50p and a 12 week average price of 60.25p.
The 1 year high share price is 89.50p while the 1 year low share price is currently 60.25p.
There are currently 78,543,318 shares in issue and the average daily traded volume is 93,044 shares. The market capitalisation of Optibiotix H. is £52,624,023.06.
21/6/2017
20:42
bdog51: Whilst it's somewhat disappointing to see the OPTI share price stagnate yet again, take a look at 4D Pharma.. down from 800p to 250p in the last 8 months. I always thought 4D was overvalued, yet it didn't stop Woodford piling in big time.Meanwhile with OPT in the 60s I'm a buyer as I believe we're going to hit the big time in due course, many hot irons in the fire here. Revenue forecasts will drive the re-rate.
10/6/2017
18:53
parob: riskybusiness1 - 06 Jun 2017 - 09:09 - 24143 of 24143 - 0I wrote to walbrook over the weekend asking about ysf and how some believe they are at fault for suppressing the share price through dropping on market. Also asked for any future revenue indications. Some of it didn't actually relate to what I asked but interesting nevertheless I assume from soh:'This is an incorrect assumption as the YSF is not selling down shares in drip sales. As a regional investment fund its reason d'aitre is to support new investments and occasionally it has to sell shares to allow it to reinvest or to bid for external funds. We are fortunate that our institutional investors are very supportive of OptiBiotix and when there is a need to sell shares rather than put them on the market they will often approach us first. This allows OptiBiotix to place shares with interested institutional investors who are looking for large amounts of shares but are unlikely to buy small amounts in the market. With a large volume this is often at a market discount which temporarily affects the share price. Please note that all market sensitive information is shared with all investors and 'institutional investors' do not have access to any information which is not available in the market. I am particularly keen on this and hence I gave exactly the same presentation to retail investors at the recent evening presentation that was used for institutional investors during the day. The company does not release news to buoy the share price and doesn't get too disconcerted by the day to day volatility in share price which is largely driven by market sentiment often influenced by bloggers. We are building a £200m+ company and are progressing through the phases of creating the science, building the IP, proving the science in laboratory and clinical studies and then commercialising innovative products. If we build the company on a solid base the share price will follow and be sustained.We are at the early stage of commercialisation of two products (SlimBiome and LP-LDL) with a third product (SweetBiotix) following later this year or the start of next. I have been pleasantly surprised at the high level of interest from companies in these products and we anticipate a range of agreements following on from our launch in Vitafoods. These should start to feed through in the following weeks and months whereupon we will announce to the market. As some of these deals can be worth in the regions of £5m per annum I am sure you can see that given the multiples in this industry (10-20) even if you use the lower multiple a £200m+ valuation is within reach. Share growth and company valuation has to be based on a solid foundation and I believe the next phase of share growth will come as we gain commercial traction with our products, which based on the high level of interest and 30+ ongoing discussions, look extremely promising. Investors who attend my presentation will be aware that this is all part of a structured plan and the reason we appointed a new Commercial (Per Rehne) and Sales Director (Christina Wood) in Jan 2017. They joined us at the end of March and as planned we launched products in May. As previously announced we have extensive global interest and the next few weeks and months should see these deals closing out whereupon we will announce to the market This next 18 moths should be exciting for OptiBiotix and its shareholders and hopefully, like with the Tata deal, we can announce a few surprise deals to help build the company to the next level.I am happy for this to be circulated widely as it does not contain new market sensitive information.'elrico - 06 Jun 2017 - 18:29 - 24165 of 24167 - 6Hi Stephen,I had an exchange with HLH recently (see attached) and Bathe confirmed OPTI LP-LDL will be on the shelves mid July, costs 30 capsules -18,90 € & 90 capsules-39,90 €. They ship to UK. I had a number of people asking about these, which prompted me to enquire. Google translate was helpful 😊Would it be appropriate to OPTI to disclose margin, costs for deals like this, or would this give away too much to competitors. I suspect when revenues are acknowledge and the cost base remains flat at c£1m pa, this would be clear enough.I cannot help notice your usual conservative tone has changed to one of a more upbeat, even excited and now I learn you have ventured to use projections for some of the deals being negotiated. It was also very pleasing to learn YSF are not the sole reason for holding us in the current trading range. I have long since argued YSF have a stated exit strategy of 3-6 years and aim to do so in an orderly manner. I have also argued this will be better facilitated once OPTI are able to provide number for brokers, which will enable an even more orderly exit. As one of my friends like to say, "I am sanguine."Hi,I have worked with distributors for years and they can be very difficult/disheartening so was pleasantly surprised at Vitafoods at the high level of interest in both LP-LDL and SlimBiome and can start to see a clear path to revenues of £3-6m+ per year for each of these in the not too distant future. As many people will tell you from my presentations I explain I don’t reveal margin and costs as from experience this then sets a starting point for other deals, which then become lower. This creates a risk that each deal is less profitable than the previous.Everything is building nicely and whilst there are no guarantees this is looking very promising and I would like to be announcing a number of deals in the forthcoming weeks and months. I would also like to be able to announce our plans to return value in SBTX which is a complicated process but I believe achievable.Feel free to share as this contains no market sensitive informationBest Wishes,Stephen OHara
17/5/2017
12:29
bernieboy: Don't think we are finished for the day yet. Further rises I think and I mean Opti share price!
03/5/2017
07:38
owenmo: Yes Parob - however Opti share price and RNSs in recent times demonstrate a dysfunctional relationship. Will May 3rd. be any different? But I share your view that it's a matter of time.
28/4/2017
12:20
pglancy: somuwin, i do not mind admitting i am really confused with the sbtx shares. you say. 'It seems to me that this situation with the 'free' shares is similar to any other company that decides to distribute a special dividend. i.e Company X says that they will distribute a cash divi equal to say 10% of the value of the company on a certain date. Shareholders will then receive the cash bonus, but in most cases the company's share price will drop by a similar amount (10% in this case) immediately following.' If the total investment of opti money is 650k how can the value whatever sbtx is now be wiped off the opti share price especially when the market did not see value at the time of its investment, according to soh quote.
25/4/2017
13:05
scotty1: OptiBiotix Health PLC (LON:OPTI) Q&A with CEO Stephen O’Hara: AIM Listing of Skinbiotherapeutics PLC Posted by: Amilia Stone 25th April 2017 OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with DirectorsTalk for an exclusive interview to discuss the listing of SkinBiotherapeutics PLC onto the AIM market, what this means for shareholders and how it fits in with OptiBiotix Health’s overall strategy Q1: We’ve just seen the launch of SkinBiotherapeutics PLC (LON:SBTX) separately on AIM, can you explain the rationale behind this? A1: Yes, sure. Just after listing OptiBiotix in August 2014 it became clear to me that the microbiome space was developing very rapidly and there was a window of opportunity for OptiBiotix to capitalise on our first move advantage and acquire IP in other areas in the microbiome space. There were two areas of particular interest, one was the skin microbiome and the second was the role of the microbiome in cognitive health, that is in stress, anxiety, mood etc., now, we’re still exploring opportunities in cognitive health and we’ll update shareholders if that opportunity materialises. Moving on to skin, in terms of the skin microbiome, I’ve spent 12 months identifying and accessing skin technology around the world before I finally met up with Professor Andrew McBain and Dr Catherine O’Neill in early 2015 at Manchester University. I was really impressed with Manchester University, I was impressed with their expertise, their facilities and their links to industry in particular the skin field and so I set about acquiring the rights to the technology. This took 12 months and in March 2016 we reached an agreement to acquire the IP from Manchester University for £250,000 and we set up a joint venture company called SkinBiotix Limited which OptiBiotix own 50%. However, it became clear to myself and the Board that the opportunity offered by Skin and its potential future value was not really transparent to shareholders in OptiBiotix and it’s not surprising really considering that as a young company, we’ve only been on the Stock Market for just over 2 years, we have quite a diversity of IP and quite a diversity of commercial relationships across a number of microbiome areas. There’s a reason for this, whilst this approach has complexity, it’s been designed to mitigate development risk in an evolving scientific field and provide a cost-effective way to build overlapping IP and exploit the many opportunities offered by the microbiome. So, it terms of listing Skin, the listing of SkinBiotherapeutics materialises the value of this part of the business so it’s now transparent to shareholders in OptiBiotix. OptiBiotix now owns 41.9% of a company valued and listed at £11 million which was risen over the last few days, the first few days of trading, to be £16-17 million so this means that OptiBiotix shareholders now have a significant shareholding, 42%, in an appreciating asset. More importantly, SkinBiotherapeutics has £4.5 million worth of cash to build future value in the business from these development programmes, which, similar to OptiBiotix, have targeted a very large consumer markets. So, I think it’s a great opportunity in a very exciting space. Q2: I think you’ve touched on this but what could this mean for OptiBiotix investors and is there any idea on the timing involved? A2: So, our focus really is on developing Skin and building value from these development programmes, that’s the immediate focus. As the value of SkinBiotherapeutics increases, this will of course benefit OptiBiotix, as a major shareholder, as the share price in SkinBiotherapeutics goes up, the market cap goes up, OptiBiotix as the major shareholder will benefit from that. At some point, in the not so distant future, and we have stated this time and time again but just to restate it, we want to distribute value in SkinBiotherapeutics back to OptiBiotix Health shareholders, now, this is quite a complex process, and we’re working with our advisers on the fairest way of achieving this. We can’t give exact timings on this because as I’m sure you can appreciate, this is market-sensitive information but we’ll probably link any distribution to shareholders over defined time periods for example, to shareholders who held shares continuously between two time points such as the start and end of a particular month. This overcomes the anomaly where a particular trader sells or holds a number of shares for a very short period of time and gains an undue benefit so mitigate the possibility of shareholders trading in OptiBiotix simply to gain a position in Skin, this time period will be retrospective so for example, if we were looking to distribute value in the Autumn then we’d link that to shares held over a period of time in the preceding Spring. So, just to reemphasise this is just an example, the mechanism, the timing of any distribution of value has yet to be determined and would depend very much on the SkinBiotherapeutics’ progress and market conditions. Our overall aim is to ensure the best long-term approach of building value in OptiBiotix to the benefit of all its shareholders. Q3: How does this fit in with OptiBiotix Health PLC’s overall strategy? A3: We announced this strategy back in July last year and the listing of SkinBiotherapeutics reflects a strategy to realise the growing value of each division which the Board believes is currently not being fully realised when viewed as a whole. So, typically, shareholders look at OptiBiotix Health and judge it on the basis of its products that are closer to market but as we’ve shown with Skin, which is quite early in its development, the value of that was not fully realised until we listed it on the Stock Market. This strategy allows investors in OptiBiotix to build up a broad-based investment portfolio across a number of areas in the microbiome space, which diversifies risk, whilst offering shareholders multiple opportunities in this really exciting space. As each listed company grows in value, OptiBiotix shareholders will benefit from the appreciation of each asset and this is a really exciting and innovative business model which, over time, looks to give OptiBiotix shareholders a position in multiple companies which is a prospect of multiple returns. So, it’s a good time for OptiBiotix Health shareholders and we’re determined to, mentioned at the very beginning, to build value in Skin and to turn some of that value to shareholders as time goes on.
12/4/2017
10:15
shrewdmole: Guys I've kept a bit quiet as tbh there's been so much second guessing and regurgitated facts and fiction it's been hard to read some days. Put simply soh has now told us what will happen with Sbtx, the Manchester evening news has suggested what I've kind of that and posted that the platforms and findings are further advanced than we may think. As for the Opti share price I didn't think I'd get another chance at these levels so although it's meant reducing elsewhere I ha e added a few this morning. I keep staring the obvious but soh is the largest private investor in Opti and his family have previously taken part in placings. Whatever he does will be to the benefit of pi's. Name another CEO on aim that has consistently done what he has said he will do, and with a low cash burn. The list of facets to this company is phenomenal, and growing with further products on shelves next month, Sbtx floated and fully funded, sugar going well, go figure seemingly growing and blue chip distribution partners. It's all got a bit microview on here and sometimes it's better to look at the bigger picture. As for level 2 there's just 1 MM been driving the offer side down for the last few days. Maybe they have an order but I'd be guessing. Once they've done what they need to do we will be back to 85-90p in no time. For any doubters, sell. But would you rather be in or out of Opti over the coming months. Let's see what else soh delivers in terms of partners. Sm
08/4/2017
08:39
michaelmouse: pglancy - I have stated my argument in post 1137. SOH's strategy will be great for shareholders if the share price of SBTX continues to appreciate. I have no problem with that. However, SOH understandably only lists the positive outcomes. Taking each of his points in turn. 1) Imo the current market cap. of SBTX is nonsense for a non-revenue generating company that is at least two years from any commercialisation. 2) The asset is appreciating since listing but it doesn't mean the share price will keep rising. If it starts to fall it will be a depreciating asset. 3) The IPO was a fund raise. Will it need more along the way? I expect it will. We shall see. 4) How? OptiBiotix and SBTX are still several years away from generating Free Cash Flow, if indeed they ever achieve it. Where will the funds come from to grant any sort of dividend? SOH says they have no intention in selling their SBTX shares (or presumably distributing them to shareholders?). 5) Only if one or more spin-offs are highly successful, and Opti retains a sufficiently large holding in each. The share price of SBTX has gone bananas since the IPO. This is not an unusual occurrence at the moment. It appears to me that it is being driven by speculators (short term traders). I wrote a blog about this recently. It's worth looking at what happened to the share prices once reality set in weeks later. I was correct. hTTp://michae1mouse.blogspot.co.uk/2016/09/should-i-be-fuming-at-missing-out-why.html FUM did quickly raise more cash at a substantial discount to the toppy share price rise and has settled at about or below the placing level. IEH and MOS have fallen back far more sharply than they rose. More recently, and perhaps more pertinently DDDD has fallen back sharply, and only yesterday I watched the rise and fall of ZOO. ZOO had been on my monitor for a while since it's an interesting micro-cap. I never bought shares because of it's balance sheet. When I saw the shares soaring this week I thought perhaps a bid was on the way and I'd missed out. Not so. The company clearly did need cash and hastily issued a RNS yesterday at midday to warn that a cash raise was on the way at what I'd imagine is a severely discounted price to yesterday's highs. My point is that fundamental value always wins out in the end. Fundamental value and current share price can become hugely detached. Imho Opti and sbtx are severely overvalued and I expect in time reality will catch-up. However, I have no idea when this might be. I have no problem with you preferring the optimism of SOH's strategy, I just don't share it. The company might be a great success in a few years time, but the share price already has much of this expectation built in.
06/4/2017
12:21
nicktopten: OPTi share price has rallied significantly since start of year. It was low 60s then with market cap of just above 50 mill. We now have 2 companies with total market cap of 80 million currently. So all I can say at this point is ...Happy Days!! If my rose tinted specs don't need cleaning, then Soh has done us proud with strategy , timing etc on all fronts. Looking forward to the coming months....
05/4/2017
08:13
suzypink: Whats your thinking re the OPTI share price? Was hoping this would have continued its climb from the last few days. Do you think this might drop back into low 70s again until money on the table. Hope not .. OPTI brings down whole portfolio as biggest holding on a day to day basis. Just believing in the long run will be the best move I made a year ago !
Optibiotix H. share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170722 11:00:38